TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04431778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Description: Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks).
Study: NCT02705573

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: In the study, mannitol 20% with a dose of 1g / kg / BW (5 ml / kg / BW) will be compared to placebo with NaCl 0.9% in the dose of 5 ml / kg / BW. The study medication will be administered immediately before organ reperfusion. The follow-up of the study is 24 hours.
Study: NCT02164149

Intervention type: OTHER
Intervention: Patients with primary colon cancer
Description: CT scan two days after surgery
Study: NCT01166464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text messaging for smoking cessation
Description: A 7-week program of daily text messages
Study: NCT03323476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation (or not initiation) of Immunosuppressive Therapy
Description: Discontinuation (or not initiation) of Immunosuppressive Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
Description: Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
Study: NCT02002195

Intervention type: DRUG
Intervention: FOLFOX
Description: Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.

Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
Study: NCT01234714

Intervention type: OTHER
Intervention: Non-invasive Magnetic Resonance Imaging (MRI)
Description: Conventional pre-operative MRI

Intervention type: PROCEDURE
Intervention: Major liver resection
Description: Hepatectomy of \>= 3 liver segments
Study: NCT03479684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gene-directed dosage of warfarin
Description: the first day given model prediction dose \* 1.5 times（\<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard dosage of warfarin
Description: the first day given 4.5mg; adjusted dose based on INR from the second day
Study: NCT04483219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI ± anti-PD-1 antibody
Description: After one cycle of TKI, evaluations would be performed according to RECIST v 1.1. (1) obvious response (A): CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic targets ≥15%; (2) general response (B): enlarged SD; (3) poor response (C): PD. TKI ＋ anti-PD-1 antibody will be administered in group A. The subjects in group C will exit the study. The subjects in group B will continue TKI for another one cycle, the obvious response subjects will entered group A, the general response subjects will keep in arm B and continue the TKI monotherapy, and the poor response subjects will exit the study.~1. Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w. (The investigators decide to choose fruquintinib or regorafenib)~2. Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years.
Study: NCT04297267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250mg/m2,d1,d8,every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75mg/m2,d1，every 3 weeks
Study: NCT04032262

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Gastrointestinal and Parkinson's Disease
Description: Subjects with Parkinson's disease will come for visits that will contain questionnaires about their PD, their bowel movements, and do further tests using anal rectal probes to understand further their constipation, and other tests to gather data on their digestion.
Study: NCT01235416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 706
Description: In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 706
Description: In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 706
Description: In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)
Study: NCT02907957

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FLIR ONE
Description: Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: FLIR ONE
Description: Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia - Caudal Nerve Block
Description: Nerve block placement as a pain management strategy indicated for certain urological and lower extremity surgeries.
Study: NCT01166464

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Generic text messages
Description: non-smoking related text messages will be given on the same daily schedule as matches the active intervention to establish a control for contact time.
Study: NCT01137864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious disease specialist advice
Description: Indication, choice, dosing and duration of antimicrobial therapy
Study: NCT03599726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 5 mg per day for week 1-2 or 5-6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 5 mg per day for week 1-2 or 5-6
Study: NCT02631031

Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan
Description: single oral dose of 160 mg valsartan under fasting conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan
Description: single oral dose of 160 mg valsartan under fasting conditions
Study: NCT03015779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cultured autologous oral mucosal epithelial cell sheet
Description: a prospective study,Before and after self control
Study: NCT02462837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02666807

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Ginger 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks
Study: NCT06082505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education will be delivered in person in a group education setting or individually by phone. Group education will include 1 hour breast and cervical cancer prevention education session delivered with support of electronic presentations. For phone education, trained project staff or Community Health Workers (CHWs) will deliver telephone-based education as an alternative to group education session for women who missed scheduled session twice (education materials would be printed and mailed).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education will be delivered in person in a group education setting or individually by phone. Group education will include 1 hour breast and cervical cancer prevention education session delivered with support of electronic presentations. For phone education, trained project staff or Community Health Workers (CHWs) will deliver telephone-based education as an alternative to group education session for women who missed scheduled session twice (education materials would be printed and mailed).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation to clinic
Description: Continue telephone based navigation tailored to participants' barriers using the Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation to clinic
Description: Continue telephone based navigation tailored to participants' barriers using the Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
Study: NCT01939080

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training with supervised sessions
Study: NCT03136094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT+12
Description: The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants received caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SBIRT+Usual Care
Description: Patients receive usual SBIRT care
Study: NCT02534155

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MitraClip®
Description: one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve Surgery
Description: Repair or replace mitral valve
Study: NCT02827370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Receive dietary counseling
Study: NCT01844986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 300mg tablets
Description: Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olaparib 300mg tablets
Description: Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
Study: NCT03142334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT02499328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736
Study: NCT04260607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The experimental and placebo arms will receive a single dose of IV ketamine, 0.5 mg/kg in 100 cc NS or 100 cc of NS infused over 40 minutes.~3. Post ketamine re-evaluation of outcome measures at four and twenty-four hours will determine clinical effectiveness of ketamine intervention~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post ketamine re-evaluation of outcome measure at one-week post infusion will elucidate ketamine's durability of effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The placebo arms will receive a single dose of 100 cc of NS infused over 40 minutes.~3. Post Placebo infusion re-evaluation of outcome measures at four and twenty-four hours~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post Normal Saline re-evaluation of outcome measure at one-week post infusion.
Study: NCT03254641

Intervention type: DRUG
Intervention: human chorionic gonadotropin
Description: 5000 IE times one
Study: NCT02499328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736
Study: NCT03680508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-022 and TSR-042
Description: immunotherapy
Study: NCT03251664

Intervention type: DIETARY_SUPPLEMENT
Intervention: Food groups consumed

Intervention type: DIETARY_SUPPLEMENT
Intervention: Food groups consumed
Study: NCT01923168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpelisib
Description: BYL719 + Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buparlisib
Description: BKM120 + Letrozole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (of BYL719 or BKM120) + Letrozole
Study: NCT01466595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
Study: NCT00487435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol (CG5503) Extended Release (ER)
Description: 100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
Study: NCT01633281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Ten sessions of acupuncture at 2x per week over 5 weeks will be given to patients. The acupuncture points include a standard set of obligatory points and additional points based on symptoms.
Study: NCT02827682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angel-6000D Multiparameter Anesthesia Monitor (IoC)
Description: The Angel-6000D Multiparameter Anesthesia Monitor, Shenzhen Weihaokang Medical Technology Co., Ltd, Guangdong, China

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BIS VISTA Monitor (BIS)
Description: BIS VISTA Monitor, Covidien, Changchun city shi jia trade co., Ltd, Changchun, China
Study: NCT05276986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOMS protocol
Description: For a maximum repetition of the trunk muscles, two measurements were made with a 45-second rest interval.The values were recorded in Newtons by taking the maximum value of the two repetitions measured. DOMS was formed by eccentric contraction with 80% of this determined value.To generate DOMS in the trunk, participants were seated on the bench with the knees flexed at 90° and the soles of the feet in full contact with the floor, keeping the weight at 80% of the predetermined maximum repetition.The participants were asked to perform trunk extension with eccentric contraction of the trunk in 5 seconds, and trunk flexion with concentric contraction in 3 seconds.Two-minute rests between sets and 45-second rests between repetitions were given.The date and time of the created DOMS were recorded and the measurements were repeated at the 24th and 48th hours.
Study: NCT00873990

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total etch bonding agent (5th generation)
Description: Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch and rinse bonding system (two step bonding agent) will be treated with 37% phosphoric acid (Total Etch Ivoclar Vivadent) for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved.~Adper Single Bond 2 (3M ESPE) will be applied to occlusal fissure using applicator brushes followed by curing for 10 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self etch (7th generation ) bonding agent
Description: For teeth selected for application of self etching bonding agent (Adper Easy Bond 3 M), the bonding agent will be applied to occlusal surface with microbrushes and will be left undisturbed for 20 seconds followed by air drying for 5 seconds and then will be light cured for 10 seconds. Fissure sealant (Clinpro 3M ESPE) will be applied in a similar manner as for etch and rinse group and light cured.
Study: NCT00582205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin IP
Description: Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles
Study: NCT04327401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone administration for 10 consecutive days after randomization.
Study: NCT03173651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Williams airway
Description: This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group W

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Guedle's airway
Description: This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA MADgic airway
Description: This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group M
Study: NCT04044027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S.P.A.R.K (Speaking to the Potential, Ability and Resilience inside Kids) Teen Pregnancy Prevention and Mentoring
Description: S.P.A.R.K is a curriculum-based group intervention for youth ages 11-17 living in out-of-home foster care. The curriculum consists of 23 topical lessons made up of a combination of educational and interactive activities on each topic. The curriculum covers four Adult Preparation Subjects (healthy relationships, educational and career success, healthy life skills, adolescent development) as well as mentoring, bully prevention, emotional competency, self-efficacy, communication, conflict resolution, and pregnancy prevention.
Study: NCT03210662

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT00986102

Intervention type: DRUG
Group type: OTHER
Intervention: doripenem
Description: 500mg vial by injection every 8 hours for 5 to 14 days
Study: NCT02499328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: AZD5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: AZD5069
Study: NCT04778072

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate 14mg once daily
Description: ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily with matching placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate 25mg once daily
Description: ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily with matching placebo
Study: NCT03671148

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for risankizumab administered by subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for risankizumab administered by subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection